OSI 930

Drug Profile

OSI 930

Alternative Names: OSI-930

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator OSI Pharmaceuticals
  • Class Antineoplastics; Quinolines; Small molecules; Thiophenes
  • Mechanism of Action Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in United Kingdom (PO, Tablet)
  • 07 Oct 2010 OSI completes a phase I trial (NCT00513851) in late-stage Solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top